Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,068.2
-9.8 (-0.32%)

 

  • STI Straits Times Index
    3,068.2
    -9.8 (-0.32%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,696.1
    -11.9 (-0.70%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,633.2
    31.3 (0.12%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,630.5
    31.6 (1.22%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    22,269.9
    19.6 (0.09%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,777.1
    -97.1 (-1.65%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,080.4
    -5.7 (-0.27%)
    Index delayed 20 minutes
  • XAO XAO
    6,027.2
    16.2 (0.27%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 604.5M
  • Value: 721.7M
  • Rise: 117
  • Fall: 183
  • Unch: 546

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Genting Sing0.940-0.010
Rex Intl0.079-0.001
Ezion0.047-0.002
Spackman0.028-0.005
Advance SCT0.001-
KLW0.004+0.001
Thomson Medical0.079-
YZJ Shipbldg SGD1.270-0.030
SingTel3.050-0.050
Hu An Cable^0.008-0.001

World Indices

World Indices
Name Last Change
Nasdaq 7,406.9 -124.0
HSI 25,633.2
HSCEI 10,440.3
Jakarta 5,777.1
Nikkei 225 22,269.9
SSE Comp 2,630.5
Shanghai A 2,754.7
Shanghai B 276.5
ShenZhen A 1,423.8
ShenZhen B 896.2
Taiwan W 9,831.2
PSE Comp 0.0
KOSPI 2,080.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

QT Vascular QT VASCULAR LTD.
Quotes 10 Minutes Delayed. Updated at 12 Nov 2018 17:01
Last (SGD): 0.011 Change: - High: 0.011 Remarks: -
Change (%): - Low: 0.010
Open 0.010 Yesterday's Close 0.011
Buy Price 0.010 Sell Price 0.011
Buy Volume ('000) 506.0 Sell Volume ('000) 7,460.0
Cumulative Volume ('000) 2,501.0 Cumulative Value 25,011
 
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.01653 Trailing EPS (SGD) e 0.01845 NAV (SGD) b 0.0181
PE a - Trailing PE f 0.596 Price / NAV b 0.6077
Dividend (SGD) d - Cash In Hand (SGD) g 0.0139 Issued & Paid-up Shares c 2,092,632,000
Dividend Yield (%) d - Price / Cash In Hand g 0.791 Treasury Shares h -
Beta - 75 Daysi 0.049 R-Squared - 75 Days(%)i 0.01 Market Cap (M) 23.019
Beta - 500 Daysi 0.853 R-Squared - 500 Days (%)i 1.00 Enterprise Value (M) -2.319
Piotroski F Score 2 Exchange Code 5I0 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 58.1117 6-Month VWAP 0.014 Free Float (%) 92.5
Under CPF Investment Scheme (CPFIS) Yes
Sector & Industry Manufacturing - Biotechnology
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 20 Aug 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference QT Vascular SGX 23.019 - 0.596 0.6077 -
Industry Biotechnology SGX 1,989.882 6.262 4.801 0.6797 4.677
Medical & Biotechnology SGX 1,044.248 20.565 18.562 1.2884 1.888
Index FTSE ST Catalist Index SGX 81.269 - - 0.8500 1.828
Local Peer Lonza SGX 5,937.213 5.989 4.911 0.6806 4.702
Local Peer Suntar Eco-City^ SGX 9.414 - - 0.4573 -
Global Peer AMGEN INC NASDAQ 123,085.222 62.196 55.897 8.5780 2.699
Global Peer GILEAD SCIENCES INC NASDAQ 92,079.872 19.896 58.021 4.0278 2.955
Global Peer AMGEN-T HKEx 637,219.000 41.319 36.620 5.6753 4.063
Global Peer BIOGEN INC NASDAQ 65,522.272 25.805 20.562 4.7595 -
Global Peer CSL ASX 87,362.009 39.153 39.153 15.8208 1.182
Global Peer CELGENE CORP NASDAQ 51,758.633 17.605 17.897 10.6499 -
Global Peer ILLUMINA INC NASDAQ 48,399.750 66.758 70.760 13.8167 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 46,140.997 175.313 71.339 15.8773 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 38,602.863 32.209 21.475 4.9061 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,539.094 62.123 180.466 3.0033 -
Other Global Peers AGILENT TECHNOLOGIES INC (NYSE), BIOMARIN PHARMACEUTICAL (NASDAQ), INCYTE CORPORATION (NASDAQ), SINO BIOPHARM (HKEx), TILRAY INC (NASDAQ), WUXI BIO (HKEx), NEUROCRINE BIOSCIENCES INC (NASDAQ), SEATTLE GENETICS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BEIGENE-B (HKEx), BLUEBIRD BIO INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), ALKERMES PLC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), LOXO ONCOLOGY INC (NASDAQ), EXELIXIS INC (NASDAQ), 3SBIO (HKEx), IMMUNOMEDICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ARRAY BIOPHARMA INC (NASDAQ), FIBROGEN INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), LIGAND PHARMACEUTICAL INC (NASDAQ), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), GENOMIC HEALTH INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACCELERON PHARMA (NASDAQ), REGENXBIO INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ENDOCYTE INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), ANAPTYSBIO INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), OPKO HEALTH INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), TESARO INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), MIRATI THERAPEUTICS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), INSMED INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), ASCLETIS-B (HKEx), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), RETROPHIN INC (NASDAQ), NATERA INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), IMMUNOGEN INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), FATE THERAPEUTICS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), INFLARX N V (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ACCELERATE DIAGNOSTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), MESOBLAST LTD (ASX), CARA THERAPEUTICS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), MACROGENICS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RADIUS HEALTH INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NOVAVAX INC (NASDAQ), AVROBIO INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), OMEROS CORP (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), ARVINAS INC (NASDAQ), VERACYTE INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), INSYS THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), CKLIFE SCIENCES (HKEx), PROTHENA CORP PLC (NASDAQ), LEE'S PHARM (HKEx), NANOSTRING TECHNOLOGIES INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), CORIUM INTERNATIONAL INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), SINOVAC BIOTECH (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), DERMIRA INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), MEDICINOVA INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ZAFGEN INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), ESSEX BIO-TECH (HKEx), FIVE PRIME THERAPEUTICS (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), VERASTEM INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), KERYX BIOPHARMACEUTICALS (NASDAQ), CYTOKINETICS INC (NASDAQ), SAVARA INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), RESTORBIO INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), MERUS B V (NASDAQ), MIMEDX GROUP INC (NASDAQ), GERON CORP (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), KADMON HLDGS INC (NYSE), CASI PHARMACEUTICALS INC (NASDAQ), RTI SURGICAL INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), ADURO BIOTECH INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), POLYNOVO LIMITED (ASX), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), EQUILLIUM INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ATHERSYS INC (NASDAQ), TOCAGEN INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), AXOVANT SCIENCES LTD (NASDAQ), AFFIMED N V (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), IMV INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AGENUS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), NANTKWEST INC (NASDAQ), KAMADA (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), SYNLOGIC INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ARDELYX INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), CCMDBIO (Bursa), BBI LIFE SCI (HKEx), CONTRAFECT CORP (NASDAQ), CHIMERIX INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), COHBAR INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ENZO BIOCHEM INC (NYSE), HARVARD BIOSCIENCE INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), MERSANA THERAPEUTICS INC (NASDAQ), SESEN BIO INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), STANDARD DIVERSIFIED INC (NYSE American), VBI VACCINES INC CDA (NASDAQ), TELIX PHARMACEUTIC (ASX), SELECTA BIOSCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), XOMA CORP (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), PFENEX INC (NYSE American), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), IMMUTEP LTD (ASX), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CORREVIO PHARMA CORP (NASDAQ), CHIASMA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), PORT (SET), BIOXCEL THERAPEUTICS INC (NASDAQ), OPHTHOTECH CORPORATION (NASDAQ), ORGENESIS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), EVOFEM BIOSCIENCES INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), ITERUM THERAPEUTICS PLC (NASDAQ), AVITA MEDICAL LTD (ASX), ARAVIVE INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), REGENT PACIFIC (HKEx), EVOGENE LTD (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), IMMUNE DESIGN CORP (NASDAQ), UNI-BIO GROUP (HKEx), VACCINEX INC (NASDAQ), EDAP TMS S.A. ADS EACH REPR 1 ORD SHARE FRF0.8 (NASDAQ), IBIO INC (NYSE American), BIONANO GENOMICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ASTERIAS BIOTHERAPEUTICS INC (NYSE American), OPIANT PHARMACEUTICALS INC (NASDAQ), ONCOBIOLOGICS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), ONCOMED PHARMACEUTICALS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), CT ENTERPRISE (HKEx), GENOCEA BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), AQUINOX PHARMACEUTICALS INC (NASDAQ), BIONOMICS LTD (ASX), TREVENA INC (NASDAQ), PHYLOGICA LIMITED (ASX), RESAPP HEALTH LIMITED (ASX), IMUGENE LIMITED (ASX), SUNESIS PHARMACEUTICALS INC (NASDAQ), CURIS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ORAGENICS INC (NYSE American), CATABASIS PHARMACEUTICALS INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), VERMILLION INC (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), BIOTRON (ASX), ONCOLYTICS BIOTECH INC (NASDAQ), ADVAXIS INC (NASDAQ), GTX INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), ACTINOGEN MEDICAL LTD (ASX), REXAHN PHARMACEUTICALS INC (NYSE American), PROTEON THERAPEUTICS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), HISTOGENICS CORP (NASDAQ), BENITEC BIOPHARMA LTD (ASX), CAPRICOR THERAPEUTICS INC (NASDAQ), REGENEUS LTD (ASX), APTOSE BIOSCIENCES INC (NASDAQ), PHOSPHAGENICS LTD (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), VICAL INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADR EA REPR 2 ORD SHS (NYSE American), CEL-SCI CORP (NYSE American), OVASCIENCE INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), ADALTA LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PATRYS LIMITED (ASX), AETERNA ZENTARIS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), EDGE THERAPEUTICS INC (NASDAQ), ISORAY INC (NYSE American), GENETIC TECHNOLOGIES (ASX), CELLMID LIMITED (ASX), SENESTECH INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), ARSANIS INC (NASDAQ), RHINOMED LIMITED (ASX), SOLIGENIX INC (NASDAQ), LIVING CELL TECHNOLOGIES (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), COLLPLANT HOLDINGS LTD SPON ADR EACH REP 50 ORD(POST REV SPLT) (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VAXART INC (NASDAQ), ATYR PHARMA INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADR EA REPR 150 ORD(POST SPLIT) (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), TROVAGENE INC (NASDAQ), ORTHOCELL LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), ANATARA LIFESCIENCES LTD (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRANA BIOTECHNOLOGY (ASX), KAZIA THERAPEUTICS LIMITED (ASX), BIOXYNE LIMITED (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), PRANA BIOTECHNOLOGY SPON ADR EA REPR 60 ORD (POST REV SPLIT) (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), VITAL THERAPIES INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), MICROBOT MEDICAL INC (NASDAQ), HAO WEN HLDGS (HKEx), HOLISTA COLLTECH LIMITED (ASX), OHR PHARMACEUTICAL INC (NASDAQ), ANTEO DIAGNOSTICS LIMITED (ASX), MIDATECH PHARMA PLC SPON ADR EACH REP 2 ORD SHS (NASDAQ), RXI PHARMACEUTICALS CORP (NASDAQ), OPGEN INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), NEURALSTEM INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), MEMPHASYS LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), MEGASUN (Bursa), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), ALLIQUA BIOMEDICAL INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), BIOCEPT INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADR EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), TBG DIAGNOSTICS LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), PRECIPIO INC (NASDAQ), MGRC (Bursa), BIO-PATH HOLDINGS INC (NASDAQ), MEDIBIO LIMITED (ASX), STELLAR BIOTECHNOLOGIES INC (NASDAQ), BIOBLAST PHARMA LTD (NASDAQ), CCP TECHNOLOGIES LTD (ASX), NANOLLOSE LTD (ASX), AURIS MEDICAL HOLDING AG (NASDAQ), CYTORI THERAPEUTICS INC (NASDAQ), BPH ENERGY LIMITED (ASX), INTELLIPHARMACEUTICS INTL INC (NASDAQ), ALCHEMIA LIMITED (ASX), AMPLIPHI BIOSCIENCES CORPORATION (NYSE American), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), GENERA BIOSYSTEMS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days --0.001
-8.33 %
Medium Term Return 3 Months --0.002
-15.38 %
6 Months --0.005
-31.25 %
1 Year --0.006
-35.29 %
Long Term Return 2 Years --0.093
-89.42 %
3 Years --0.114
-91.20 %
Annualised Return Annualised --
-55.52 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.009 - 0.022 Change From 1 Year Low +0.002 % Change From 1 Year Low (%) +22.22
Change From 1 Year High -0.011 % Change From 1 Year High (%) -50.00
2 Years Range 0.006 - 0.115 Change From 2 Years Low +0.005 % Change From 2 Years Low (%) +83.33
Change From 2 Years High -0.104 % Change From 2 Years High (%) -90.43
5 Years Range 0.006 - 0.560 Change From 5 Years Low +0.005 % Change From 5 Years Low (%) +83.33
Change From 5 Years High -0.549 % Change From 5 Years High (%) -98.04
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

The Group is engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases. The Group collaborates with industry specialists and physicians who are key opinion leaders to develop and offer physicians and patients new and differentiated devices to improve outcomes in complex peripheral and coronary interventions.

IPO Performance

Listing Date 29 Apr 2014 Full Subscription Rate (x) -
No of Placement Shares (M) 196.43 No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) 0.280 First Day Close (SGD) 0.340 First Week Close (SGD) 0.345
Current vs IPO Price (%) -96.07 First Day Gain (%) +21.43 First Week Gain (%) +23.21

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2017 Dec 2017 Part 1(0.91 MB)
Part 2(0.08 MB)
Annual Report 2016 Dec 2016 Part 1(1.60 MB)
Part 2(0.47 MB)
Annual Report 2015 Dec 2015 Part 1(0.82 MB)
Part 2(0.20 MB)
Annual Report 2014 Dec 2014 Part 1(2.05 MB)
Part 2(0.42 MB)
Annual Report 2013 Dec 2013 Part 1(1.04 MB)
IPO Prospectus
IPO Prospectus 2014 Apr 2014 Part 1(3.55 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
12 Nov 2018 0.010 0.011 0.010 0.011 2,501,000 0.0100
09 Nov 2018 0.010 0.011 0.010 0.011 2,656,700 0.0100
08 Nov 2018 0.010 0.011 0.009 0.011 9,801,400 0.0099
07 Nov 2018 0.011 0.011 0.010 0.010 15,020,200 0.0101
05 Nov 2018 0.011 0.011 0.011 0.011 580,000 0.0110
02 Nov 2018 0.011 0.011 0.011 0.011 2,500,000 0.0110
01 Nov 2018 0.011 0.011 0.011 0.011 1,800,000 0.0110
31 Oct 2018 0.011 0.012 0.011 0.012 3,020,200 0.0110
30 Oct 2018 0.011 0.012 0.011 0.011 1,902,100 0.0110
29 Oct 2018 0.011 0.011 0.011 0.011 914,000 0.0110
26 Oct 2018 0.011 0.012 0.011 0.012 888,000 0.0110
25 Oct 2018 0.010 0.012 0.010 0.011 3,710,100 0.0109
24 Oct 2018 0.011 0.011 0.010 0.011 11,642,600 0.0110
23 Oct 2018 0.011 0.011 0.011 0.011 - -
22 Oct 2018 0.011 0.011 0.011 0.011 - -
19 Oct 2018 0.011 0.011 0.011 0.011 900,000 0.0110
18 Oct 2018 0.012 0.012 0.012 0.012 8,164,400 0.0120
17 Oct 2018 0.011 0.012 0.011 0.012 2,103,000 0.0117
16 Oct 2018 0.011 0.012 0.011 0.011 760,000 0.0117
15 Oct 2018 0.011 0.012 0.011 0.012 150,000 0.0113
12 Oct 2018 0.012 0.012 0.012 0.012 2,540,000 0.0120
11 Oct 2018 0.011 0.012 0.011 0.012 5,751,600 0.0119
Summary
Current 2 Weeks
(29 Oct 2018 to 12 Nov 2018)		 0.011 0.012 0.009 0.011 40,695,600 -
Previous 2 Weeks
(15 Oct 2018 to 26 Oct 2018)		 0.011 0.012 0.009 0.012 28,318,100 -
4 Weeks from
(17 Sep 2018 to 12 Oct 2018)		 0.011 0.012 0.009 0.012 62,153,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.